We can’t show the full text here under this license. Use the link below to read it at the source.
Meta-Analysed Numbers Needed to Treat of Novel Antidiabetic Drugs for Cardiovascular Outcomes
Number of Patients Needed to Treat with New Diabetes Drugs to Improve Heart Health: A Meta-Analysis
AI simplified
Abstract
Meta-analysis of 13 studies with 96,860 patients shows Meta-NNTs for cardiovascular mortality of 178 for DPP-4 inhibitors, 261 for GLP-1 receptor agonists, and 118 for SGLT2 inhibitors.
- Thirteen studies reported modest treatment benefits of GLP-1 receptor agonists and SGLT2 inhibitors for cardiovascular mortality in primary type 2 diabetes populations.
- DPP-4 inhibitors showed a Meta- of 178, while GLP-1 receptor agonists had a Meta-NNT of 261, indicating relative treatment effects.
- SGLT2 inhibitors demonstrated a lower Meta-NNT of 118 for cardiovascular mortality compared to other drug classes.
- For hospitalization due to heart failure, ten studies analyzed 96,128 patients, revealing a Meta-NNT of -644 for DPP-4 inhibitors and 441 for GLP-1 receptor agonists.
- SGLT2 inhibitors were particularly effective in primary heart failure populations, showing a Meta-NNT of 25, compared to 233 in primary diabetes populations.
AI simplified
Key numbers
118
Meta- for cardiovascular mortality
At a median follow-up of 30 months for SGLT2 inhibitors.
126
Meta- for hospitalization for heart failure
At a median follow-up of 29 months for SGLT2 inhibitors.
25
Meta- for primary heart failure populations
At 16 months of follow-up for SGLT2 inhibitors.